IBD
Northern Lights Fund Trust IV - Inspire Corporate Bond Impact ETF
IBD
Northern Lights Fund Trust IV - Inspire Corporate Bond Impact ETF
Spyre Therapeutics maintains a 'Strong Buy' rating, driven by promising IBD pipeline progress and robust cash reserves. SYRE's three monotherapy candidates—SPY001, SPY002, SPY003—show potential best-i
BOISE, Idaho, Aug. 25, 2026 /PRNewswire/ -- Inspire Investing is pleased to announce that the Inspire Corporate Bond ETF (NYSE: IBD) has been awarded a 5-star Overall Morningstar Rating™ for the 5-yea